Latest Breaking News On - Orchestra biomed - Page 4 : comparemela.com

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis

This clinical trial compares a paclitaxel-coated balloon vs an uncoated balloon in patients with in-stent restenosis undergoing percutaneous coronary interventi

United statesEteläuomen läiAsahi inteccEdwards lifesciencesRobertw yehDrug administrationInstitute incMeeting of cardiovascular research technologiesBaim institute for clinical research incBlood instituteColumbia universitySociety for cardiovascular angiographyCardiovascular research foundationBoston scientificOutcomes researchBoston scientific corp

Orchestra BioMed Holdings, Inc (NASDAQ:OBIO) Short Interest Up 7 6% in January

Orchestra BioMed Holdings, Inc (NASDAQ:OBIO) Short Interest Up 7 6% in January
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United kingdom generalUnited kingdomPerceptive advisorsBlackrock incOrchestra biomed holdings incJefferies financial groupVanguard group incOrchestra biomed company profileCharles schwab investment management incGeode capital managementOrchestra biomed holdingsGet free reportOrchestra biomedCapital managementCharles schwab investment managementSchwab investment management

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Anticoagulation | JAMA

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

Virginia commonwealth universityUnited statesComunidad autonoma de catalunaUnited kingdomColumbia universityNew yorkKhorasane ra aviShahid beheshtiShahid modarresSistan va baluchestanAz arbayjane sharqiPooyesh darouSeyed hossein hosseiniHooman bakhshandehDavid jimenezMahdi yadollahzadeh

Orchestra BioMed (NASDAQ:OBIO) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report published on Friday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $14.00 target price on the stock. Orchestra BioMed Stock Performance Shares of OBIO opened at $8.72 on Friday. The stock has a 50-day moving […]

Barclays plcHarbour investments incOrchestra biomed holdings incAllspring global investments holdingsJefferies financial groupOrchestra biomedFree reportGet free reportGlobal investments holdingsRhumbline advisersBiomed holdingsBackbeat cardiac neuromodulation therapyVirtue sirolimus angioinfusion balloonOrchestra biomed dailyNasdaq obioInitiated coverage

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be more than 750,000 patients annually worldwide

United statesRobertc kowalDavid hochmanSuman pasupuletiAmerican college of cardiology heart associationMedtronic incAmerican heart associationOrchestra biomedCardiac pacing therapiesMedtronic cardiac rhythm managementCitrus cardiology consultantsHigh blood pressureAmerican collegeData safety monitoring boardHeart diseaseStroke statistics